VSV-N-RAS, VSV-TYRP1 or VSV-CYT-C Viruses for the Treatment of Melanoma

Technology #2012-050

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Richard G. Vile Ph.D.
Jill M. Thompson
Jose S. Pulido M.D., M.S., M.B.A.
Timothy J. Kottke
Managed By
Panya Taysavang
Patent Protection
US Patent Pending
US Patent Pending
US Patent Pending
US Patent Pending
US Patent Pending

We have shown that a combination of these vesicular stomatis viruses (VSV) that encode N-Ras, cytochrome c (ctyc), or Tyrosinase-related protein 1(TYRP1), can be used to treat melanoma. Previously, we had shown that the use of a cDNA library in packaged in VSV can treat cancer. Here we show that a combination of three particular VSVs with the cDNA of N-Ras, cyt-c and Tryp 1 given intravenously can treat melanoma.